Kissei Urges Tavneos Caution In Japan After 20 Deaths
Reports of 20 deaths, including cases of vanishing bile duct syndrome, in patients in Japan receiving Tavneos make local headlines and prompt new precautionary measures by local licensee Kissei.
Scrip - May 18, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: GSK bolsters downstream obesity strategy; Novo winning early obesity pill market; Roche’s support for Switzerland under strain; Hengrui and BMS strike huge R&D alliance; PCSK9 drug Lerochol launched in US at lower direct cost.
Scrip - May 18, 2026

Bipartisan Bill Would Clear The Way For Medical Device E-Labeling
Bipartisan House and Senate bills would let medical device and IVD manufacturers deliver instructions for use primarily through electronic channels, ending the paper-default rule. AdvaMed supports the move, while accessibility advocates warn of digital-divide gaps for older and rural users.
Medtech Insight - May 15, 2026

Veeva MedTech Summit: Baxter AI Leaders Share ‘Dos And Don’ts’ Of AI Integration
Baxter AI leaders at the Veeva MedTech Summit outlined their AI strategy, stressing the need for a governance framework, AI literacy, prioritization of high-value use cases and keeping the human in the loop while exploring agentic AI use.
Medtech Insight - May 15, 2026

Makary’s Departure Leaves ‘Pin-Drop Silence’ At FDA, Says Staffer. Others Say Good Riddance
During his 13 months running the US FDA, Marty Makary accelerated reviews, brought AI to the agency, and presided over smooth and speedy MDUFA negotiations. However, his tenure was also marked by internal instability, clashes with the White House, and poor communication with regulated industries.
Medtech Insight - May 15, 2026

ViCentra Challenges Omnipod With Smartphone Closed Loop, Eyes 2027 FDA Push
The Dutch insulin pump maker is launching its Kaleido system with Diabeloop's DBLG2 algorithm and Dexcom G7 in Germany and the Netherlands this summer – and has its sights set on the US by 2027.
Medtech Insight - May 15, 2026

Terumo Sets Sights on Top-Tier Medtech Status After Fifth Consecutive Year of Growth
Terumo posted a fifth consecutive year of record sales and previewed higher growth targets under its next strategic plan, GS31, but faces headwinds from tariff uncertainty and neurovascular competition.
Medtech Insight - May 15, 2026

MedTech Forum 2026 Podcast: CE-Marking In GB, New MHRA Regs, UK View Of EU MDR Revision
ABHI's Steve Lee says UK industry foresees friction-free future in medtech regulation.
Medtech Insight - May 15, 2026

Execs On The Move: May 4–8, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - May 15, 2026

Dexcom Targets Late 2027 G8 Launch As It Bets On Body-Adaptive CGM Technology
Dexcom unveiled the G8, a self-adapting CGM platform it calls a complete step change, while setting a 10% annual revenue growth floor through 2030. A Medicare coverage decision expected before year-end could also double its US addressable market.
Medtech Insight - May 15, 2026

MHRA Seeks To Lead World In Digital Mental Health Guidance
At RAPS Euro Convergence 2026, the UK regulator discussed its project to remove the ambiguity between wellness apps and regulated devices.
Medtech Insight - May 15, 2026

‘Seize The Global Initiative,’ MedTech Forum 2026 Tells European Leaders
Simplified regulation, more momentum towards technology adoption, better investment flows, resilience – if not quite protectionism – and above all “market access predictability in Europe.” These were the top wish-list sentiments voiced at the MedTech Forum 2026 in Stockholm, Sweden.
Medtech Insight - May 15, 2026

Las Vegas Supplement Firm’s Tall Gamble Doesn’t Measure Up To FTC Claim, Testimonial Standards
FTC says in administrative complaint that in addition to lacking competent and reliable evidence to support height growth claims for its products, Vanilla Chip used fraudulent social media ratings, posted by its employees or by consumers who received free products.
HBW Insight - May 18, 2026

Zydus-Assertio Deal: US Revenue Might Peak In 2029 But Rolvedon Promises More
Zydus' acquisition of US firm Assertio gives it an oncology asset developed by Hanmi Pharma and a growth platform. Rolvedon's US revenues might peak in 2029 as per Evaluate Pharma's data but the drug could have potential elsewhere.
Generics Bulletin - May 15, 2026

ANI Pharma’s Generics Success Continues To Bolster Rare Disease Business
ANI’s first earnings report of 2026 outlines the strategic significance of its generics business to generate meaningful cash flow to support its rare disease interests.
Generics Bulletin - May 15, 2026

‘There Is No Single, Global Go?To?Market Model For GLP?1s’ – Biocon’s Tambe Discusses Strategy
With the race for GLP-1 generics heating up in multiple territories, Biocon Ltd CEO and managing director Shreehas Tambe discusses the varying natures of global markets and the need for tailored strategies, while warning that a “race to the bottom” on pricing is not viable or responsible.
Generics Bulletin - May 15, 2026

Apotex Leapfrogs Dr Reddy’s With First Canadian Semaglutide Launch
Stealing a march on rival Dr Reddy’s, Canadian generics giant Apotex has announced the first launch of a generic version of Ozempic for diabetes in its domestic market.
Generics Bulletin - May 15, 2026

Financing Quarterly Statistics, Q1 2026
During Q1, biopharmas brought in an aggregate $35.9bn in financing and device company fundraising totaled $3bn; while in vitro diagnostic firms and research tools players raised $256m.
In Vivo - May 15, 2026

Podcast: Kurma’s €215m Fund And What It Says About European Funding Environment
Kurma Partners closed BioFund IV at €215m, €35m short of target, as Europe's biotech sector grapples with thin early-stage capital and heavy reliance on non-European investors.
In Vivo - May 15, 2026